Biological Drug Products (eBook)
744 Seiten
John Wiley & Sons (Verlag)
978-1-118-69522-7 (ISBN)
drug product development
Biological drug products play a central role in combating human
diseases; however, developing new successful biological drugs
presents many challenges, including labor intensive production
processes, tighter regulatory controls, and increased market
competition. This book reviews the current state of the science,
offering readers a single resource that sets forth the fundamentals
as well as tested and proven development strategies for biological
drugs. Moreover, the book prepares readers for the challenges that
typically arise during drug development, offering straightforward
solutions to improve their ability to pass through all the
regulatory hurdles and deliver new drug products to the market.
Biological Drug Products begins with general
considerations for the development of any biological drug product
and then explores the strategies and challenges involved in the
development of specific types of biologics. Divided into five
parts, the book examines:
* Part 1: General Aspects
* Part 2: Proteins and Peptides
* Part 3: Vaccines
* Part 4: Novel Biologics
* Part 5: Product Administration/Delivery
Each chapter has been prepared by one or more leading experts in
biological drug development. Contributions are based on a
comprehensive review and analysis of the current literature as well
as the authors' first-hand experience developing and testing new
drugs. References at the end of each chapter serve as a gateway to
original research papers and reviews in the field.
By incorporating lessons learned and future directions for
research, Biological Drug Products enables pharmaceutical
scientists and students to improve their success rate in developing
new biologics to treat a broad range of human diseases.
WEI WANG, PhD, is a Research Fellow for Pfizer BioTherapeutics Pharmaceutical Sciences. In addition, Dr. Wang is Adjunct Professor in the School of Pharmacy and Health Sciences at the University of the Pacific. MANMOHAN SINGH, PhD, is Head of Technical Development at Novartis Vaccines and Diagnostics. Dr. Singh has authored over 120 peer-reviewed manuscripts, reviews, and book chapters in the area of vaccine formulations and adjuvant research. He is also an Adjunct Professor at the Eshelman School of Pharmacy at University of North Carolina, Chapel Hill.
Dedication
Preface
Part 1. General Aspects 1
Chapter 1. An Overview of Discovery and Development Process For
Biologics 3
Heather H. Shih, Paula Miller and Douglas C. Harnish
Chapter 2. Nonclinical Safety Assessment of Biologics, Including
Vaccines 31
Liangbiao George Hu, David W. Clarke
Chapter 3 Clinical Assessment of Biologics Agents 57
Lesley Ann Saketkoo, Shikha Mittoo and Luis R. Espinoza
Chapter 4. Key Regulatory Guidelines for Development of
Biologics In The U.S. And Europe 75
Richard Kingham, Gabriela Klasa and Krista Hessler
Carver
Chapter 5. Landscape and Consideration of Intellectual Property
for Development Of Biosimilars 111
Srikumaran Melethil
Chapter 6. Scientific Aspects of Sterility Assurance, Sterility,
Asepsis, and Sterilization 133
James E. Akers and James P. Agalloco
Part 2. Proteins/Peptides 163
Chapter 7. Cell Cell Culture Processes in Monoclonal Antibody
Production 165
Feng Li, Amy (Yijuan) Shen and Ashraf Amanullah
Chapter 8. Protein/Peptide Purification and Virus Reduction
203
Beckley K. Nfor, Esteban Freydell and Marcel Ottens
Chapter 9. Chemical and Genetic Modification 233
M Farys, C Ginn, G Badescu, K Peciak, E Pawlisz, H Khalili and S
Brocchini
Chapter 10. Analytical Characterization of Proteins/Peptides
285
Yajun Jennifer Wang and Brian Hosken
Chapter 11. Protein/Peptide Formulation Development 323
Satoshi Ohtake and Wei Wang
Chapter 12. Regulatory Strategies and Lessons in the Development
Of Biosimilars 367
Umang S. Shah
Part 3. Vaccines 409
Chapter 13. Vaccine Development - History, Current Status
and Future Trends 411
Leo Van Der Pol and Jean-Pierre Amorij
Chapter 14. Role and Application of Adjuvants and Delivery
Systems in Vaccines 437
Rajesh K. Gupta
Chapter 15. Methods for Characterizing Proteins in Aluminum
Adjuvant Formulations 469
Martinus A.H. Capelle, Emilie Poirier and Tudor Arvinte
Part 4. Novel Biologics 487
Chapter 16. The State Of The Art and Future of Gene Medicines
489
Frank Jacobs, Stephanie C. Gordts and Bart De Geest
Chapter 17. Nucleic Acid Vaccines 531
Rachel Buglione-Corbett, John Suschak, Shixia Wang and Shan
Lu
Chapter 18. Multifunctional Polymeric Nano-Systems for Rna
Interference Therapy 569
Arun Iyer, Shanthi Ganesh, Qiong L. Zhou and Mansoor
Amiji
Chapter 19. Advent and Maturation of Regenerative Medicine
601
Abner M. Mhashilkar and Anthony Atala
Part 5. Product Administration/Delivery 629
Chapter 20. Conventional and Novel Container Closure/Delivery
Systems 631
Joseph Wong and Mahesh V. Chaubal
Chapter 21. Controlled-Release Systems for Biologics 655
Mayura Oak, Rhishikesh Mandke, Buddhadev Layek, Gitanjali Sharma
and Jagdish Singh
Chapter 22. Routes of Delivery for Biological Drug Products
677
Darrell J. Irvine, Xingfang Su and Brandon Kwong
INDEX 725
"Thus, it will be a valuable resource for both novice and
expert alike." (ChemMedChem, 1 October 2014)
Erscheint lt. Verlag | 29.8.2013 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Naturwissenschaften ► Chemie | |
Technik | |
Schlagworte | Biowissenschaften • Cell & Molecular Biology • Chemie • Chemistry • Drug Discovery & Development • Life Sciences • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung • Zell- u. Molekularbiologie |
ISBN-10 | 1-118-69522-4 / 1118695224 |
ISBN-13 | 978-1-118-69522-7 / 9781118695227 |
Haben Sie eine Frage zum Produkt? |
Größe: 4,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich